ACTU – actuate therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
Actuate Therapeutics (NASDAQ:ACTU) was downgraded by analysts at Wall St
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
Form 8-K ACTUATE THERAPEUTICS, For: Jan 12
Form 4 ACTUATE THERAPEUTICS, For: Jan 05 Filed by: THOMSON TODD S
Form SCHEDULE 13G ACTUATE THERAPEUTICS, Filed by: Voss Capital, LP
Form 144 ACTUATE THERAPEUTICS, Filed by: Kairos Venture Partners II, L.P.
Form 8-K ACTUATE THERAPEUTICS, For: Nov 28
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.